Not Invented Here

Business development professionals have long complained about the difficulty in convincing Big Pharma research groups that a new project from outside their company is worthy of consideration. This is called Not Invented Here (NIH) syndrome and, when displayed by pharma, is characterized by skepticism of novel ideas, a focus on data gaps rather than an assessment of the data that exist, and an unwillingness to abandon internal projects even if corporate portfolio valuation standards favor the external project. Read more
Recent comments on this blog
New Trump Travel Ban a Detriment to Biotech
More on the Shelf
My Biotech Heroes